Compare OSS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | IPHA |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.4M | 174.2M |
| IPO Year | 2018 | 2019 |
| Metric | OSS | IPHA |
|---|---|---|
| Price | $7.84 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.50 | $5.00 |
| AVG Volume (30 Days) | ★ 665.1K | 22.5K |
| Earning Date | 11-05-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,264,017.00 | $14,839,695.00 |
| Revenue This Year | $18.00 | $22.29 |
| Revenue Next Year | $9.93 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.33 | N/A |
| 52 Week Low | $1.85 | $1.47 |
| 52 Week High | $7.92 | $3.51 |
| Indicator | OSS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 76.57 | 45.17 |
| Support Level | $5.81 | $1.85 |
| Resistance Level | $7.92 | $1.92 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 97.87 | 25.58 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.